Amgen Inc. (AMGN) Q2 FY2026 Financial Statements: Revenue $10.05B, Net income $2.38B
More for Amgen: Company index · 10-K and 10-Q summary · 8-K filings and events
PeriodQ2 FY2026
Published
Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026, up 9.5% from a year earlier, as volume growth in products including Repatha, EVENITY and UPLIZNA outweighed biosimilar erosion of Prolia and XGEVA. Net income was $2.38 billion, up 65.9%, and diluted earnings per share were $4.37, up 64.9%. Operating income rose to $3.51 billion, up 32.3%, as lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales, and a smaller unrealized loss on Amgen's stake in BeOne Medicines added to the gain in net income.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $10,054,000,000 | up 9.5% |
| Net income | $2,375,000,000 | up 65.9% |
| Diluted EPS | $4.37 | up 64.9% |
| Operating income | $3,514,000,000 | up 32.3% |
Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. Figures calculated here, such as margins, free cash flow and trailing-twelve-month totals, have no line in a filing to point to and are not linked.
About this file
| Ticker | AMGN |
|---|---|
| CIK | 0000318154 |
| Company | Amgen Inc. |
| Business type | biopharmaceutical |
| Schema template | standard (product sales and total revenues / cost of sales / operating income / net income, plus product-level and U.S. versus rest-of-world product sales, which is how a single-segment biotechnology company is read) |
| Reporting currency | USD |
| Converted to USD | no |
| Units | actual dollars (not millions); share counts in actual shares; per-share figures in dollars |
AMGN annual income statement, balance sheet and cash flow
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Fiscal year | 2025 | 2024 | 2023 |
| Label | FY2025 | FY2024 | FY2023 |
| Period start | 2025-01-01 | 2024-01-01 | 2023-01-01 |
| Period end | 2025-12-31 | 2024-12-31 | 2023-12-31 |
| Period type | fiscal year | fiscal year | fiscal year |
| Source accession | 10-K | 10-K | 10-K |
| Income statement | |||
| Product sales | 35,148,000,000 | 32,026,000,000 | 26,910,000,000 |
| Other revenues | 1,603,000,000 | 1,398,000,000 | 1,280,000,000 |
| Total revenues | 36,751,000,000 | 33,424,000,000 | 28,190,000,000 |
| Cost of sales | 12,037,000,000 | 12,858,000,000 | 8,451,000,000 |
| Research and development | 7,272,000,000 | 5,964,000,000 | 4,784,000,000 |
| Selling general and administrative | 7,050,000,000 | 7,096,000,000 | 6,179,000,000 |
| Other operating expenses | 1,312,000,000 | 248,000,000 | 879,000,000 |
| Total operating expenses | 27,671,000,000 | 26,166,000,000 | 20,293,000,000 |
| Operating income | 9,080,000,000 | 7,258,000,000 | 7,897,000,000 |
| Interest expense net | -2,755,000,000 | -3,155,000,000 | -2,875,000,000 |
| Other income expense net | 2,651,000,000 | 506,000,000 | 2,833,000,000 |
| Income before income taxes | 8,976,000,000 | 4,609,000,000 | 7,855,000,000 |
| Provision for income taxes | 1,265,000,000 | 519,000,000 | 1,138,000,000 |
| Net income | 7,711,000,000 | 4,090,000,000 | 6,717,000,000 |
| Basic EPS | 14.33 | 7.62 | 12.56 |
| Diluted EPS | 14.23 | 7.56 | 12.49 |
| Basic shares | 538,000,000 | 537,000,000 | 535,000,000 |
| Diluted shares | 542,000,000 | 541,000,000 | 538,000,000 |
| Balance sheet | |||
| Cash and cash equivalents | 9,129,000,000 | 11,973,000,000 | |
| Trade receivables net | 9,570,000,000 | 6,782,000,000 | |
| Inventories | 6,225,000,000 | 6,998,000,000 | |
| Other current assets | 4,133,000,000 | 3,277,000,000 | |
| Total current assets | 29,057,000,000 | 29,030,000,000 | |
| Property plant and equipment net | 7,913,000,000 | 6,543,000,000 | |
| Intangible assets net | 22,276,000,000 | 27,699,000,000 | |
| Goodwill | 18,680,000,000 | 18,637,000,000 | |
| Other noncurrent assets | 12,660,000,000 | 9,930,000,000 | |
| Total assets | 90,586,000,000 | 91,839,000,000 | |
| Accounts payable | 2,367,000,000 | 1,908,000,000 | |
| Accrued liabilities | 18,523,000,000 | 17,641,000,000 | |
| Current portion of long term debt | 4,599,000,000 | 3,550,000,000 | |
| Total current liabilities | 25,489,000,000 | 23,099,000,000 | |
| Long term debt | 50,005,000,000 | 56,549,000,000 | |
| Long term deferred tax liabilities | 1,366,000,000 | 1,616,000,000 | |
| Long term tax liabilities | 2,690,000,000 | 2,349,000,000 | |
| Other noncurrent liabilities | 2,378,000,000 | 2,349,000,000 | |
| Common stock and additional paid in capital | 34,023,000,000 | 33,533,000,000 | |
| Accumulated deficit | -25,107,000,000 | -27,590,000,000 | |
| Accumulated other comprehensive loss | -258,000,000 | -66,000,000 | |
| Total stockholders equity | 8,658,000,000 | 5,877,000,000 | |
| Total liabilities and stockholders equity | 90,586,000,000 | 91,839,000,000 | |
| Shares outstanding | 538,800,000 | 536,900,000 | |
| Total debt derived | 54,604,000,000 | 60,099,000,000 | |
| Total liabilities derived | 81,928,000,000 | 85,962,000,000 | |
| Cash flow | |||
| Depreciation amortization and other | 5,167,000,000 | 5,592,000,000 | 4,071,000,000 |
| Impairment of intangible assets | 1,200,000,000 | 159,000,000 | 851,000,000 |
| Stock based compensation | 494,000,000 | 530,000,000 | 431,000,000 |
| Operating cash flow | 9,958,000,000 | 11,490,000,000 | 8,471,000,000 |
| Cash paid for acquisitions | -53,000,000 | 0 | -26,989,000,000 |
| Capex | -1,858,000,000 | -1,096,000,000 | -1,112,000,000 |
| Investing cash flow | -1,943,000,000 | -1,046,000,000 | -26,204,000,000 |
| Net proceeds from issuance of debt | 0 | 0 | 27,777,000,000 |
| Extinguishment of debt | -683,000,000 | -659,000,000 | -647,000,000 |
| Repayment of debt | -5,000,000,000 | -3,600,000,000 | -1,454,000,000 |
| Repurchases of common stock | 0 | -200,000,000 | 0 |
| Dividends paid | -5,124,000,000 | -4,832,000,000 | -4,556,000,000 |
| Financing cash flow | -10,859,000,000 | -9,415,000,000 | 21,048,000,000 |
| Free cash flow | 8,100,000,000 | 10,394,000,000 | 7,359,000,000 |
| Product sales by product | |||
| Prolia | 4,414,000,000 | 4,374,000,000 | 4,048,000,000 |
| Repatha | 3,016,000,000 | 2,222,000,000 | 1,635,000,000 |
| Otezla | 2,265,000,000 | 2,126,000,000 | 2,188,000,000 |
| Enbrel | 2,226,000,000 | 3,316,000,000 | 3,697,000,000 |
| Evenity | 2,100,000,000 | 1,563,000,000 | 1,160,000,000 |
| Xgeva | 2,084,000,000 | 2,225,000,000 | 2,112,000,000 |
| Tepezza | 1,903,000,000 | 1,851,000,000 | 448,000,000 |
| Blincyto | 1,559,000,000 | 1,216,000,000 | 861,000,000 |
| Nplate | 1,524,000,000 | 1,456,000,000 | 1,477,000,000 |
| Tezspire | 1,478,000,000 | 972,000,000 | 567,000,000 |
| Kyprolis | 1,412,000,000 | 1,503,000,000 | 1,403,000,000 |
| Aranesp | 1,389,000,000 | 1,342,000,000 | 1,362,000,000 |
| Krystexxa | 1,340,000,000 | 1,185,000,000 | 272,000,000 |
| Vectibix | 1,175,000,000 | 1,045,000,000 | 984,000,000 |
| Other products | 7,263,000,000 | 5,630,000,000 | 4,696,000,000 |
| Total product sales | 35,148,000,000 | 32,026,000,000 | 26,910,000,000 |
| Product sales by geography | |||
| United states | 25,656,000,000 | 23,301,000,000 | 19,272,000,000 |
| Rest of world | 9,492,000,000 | 8,725,000,000 | 7,638,000,000 |
| Dividends | |||
| Dividends declared | 5,228,000,000 | 4,931,000,000 | 4,644,000,000 |
| Dividends declared per share | 9.66 | 9.13 | 8.64 |
AMGN quarterly income statement, balance sheet and cash flow
| Q2 2026 | Q2 2025 | |
|---|---|---|
| Fiscal year | 2026 | 2025 |
| Fiscal quarter | 2 | 2 |
| Label | Q2 2026 | Q2 2025 |
| Period start | 2026-04-01 | 2025-04-01 |
| Period end | 2026-06-30 | 2025-06-30 |
| Period type | three months | three months |
| Source accession | 10-Q | 10-Q |
| Cash flow source accession | 0000318154-26-000124 | 0000318154-26-000124 |
| Income statement | ||
| Product sales | 9,537,000,000 | 8,771,000,000 |
| Other revenues | 517,000,000 | 408,000,000 |
| Total revenues | 10,054,000,000 | 9,179,000,000 |
| Cost of sales | 2,811,000,000 | 3,011,000,000 |
| Research and development | 1,868,000,000 | 1,744,000,000 |
| Selling general and administrative | 1,745,000,000 | 1,691,000,000 |
| Other operating expenses | 116,000,000 | 77,000,000 |
| Total operating expenses | 6,540,000,000 | 6,523,000,000 |
| Operating income | 3,514,000,000 | 2,656,000,000 |
| Interest expense net | -673,000,000 | -694,000,000 |
| Other income expense net | -73,000,000 | -394,000,000 |
| Income before income taxes | 2,768,000,000 | 1,568,000,000 |
| Provision for income taxes | 393,000,000 | 136,000,000 |
| Net income | 2,375,000,000 | 1,432,000,000 |
| Basic EPS | 4.4 | 2.66 |
| Diluted EPS | 4.37 | 2.65 |
| Basic shares | 540,000,000 | 538,000,000 |
| Diluted shares | 544,000,000 | 541,000,000 |
| Balance sheet | ||
| Cash and cash equivalents | 13,989,000,000 | |
| Trade receivables net | 10,227,000,000 | |
| Inventories | 6,220,000,000 | |
| Other current assets | 4,525,000,000 | |
| Total current assets | 34,961,000,000 | |
| Property plant and equipment net | 8,547,000,000 | |
| Intangible assets net | 20,487,000,000 | |
| Goodwill | 18,668,000,000 | |
| Other noncurrent assets | 12,976,000,000 | |
| Total assets | 95,639,000,000 | |
| Accounts payable | 2,865,000,000 | |
| Accrued liabilities | 17,192,000,000 | |
| Current portion of long term debt | 5,445,000,000 | |
| Total current liabilities | 25,502,000,000 | |
| Long term debt | 51,859,000,000 | |
| Long term deferred tax liabilities | 1,301,000,000 | |
| Long term tax liabilities | 2,844,000,000 | |
| Other noncurrent liabilities | 2,445,000,000 | |
| Common stock and additional paid in capital | 34,082,000,000 | |
| Accumulated deficit | -22,275,000,000 | |
| Accumulated other comprehensive loss | -119,000,000 | |
| Total stockholders equity | 11,688,000,000 | |
| Total liabilities and stockholders equity | 95,639,000,000 | |
| Shares outstanding | 540,600,000 | |
| Total debt derived | 57,304,000,000 | |
| Total liabilities derived | 83,951,000,000 | |
| Cash flow | ||
| Operating cash flow | 4,002,000,000 | 2,280,000,000 |
| Investing cash flow | -569,000,000 | -389,000,000 |
| Financing cash flow | -1,482,000,000 | -2,673,000,000 |
| Capex | -513,000,000 | -369,000,000 |
| Free cash flow | 3,489,000,000 | 1,911,000,000 |
| Product sales by product | ||
| Repatha | 953,000,000 | 696,000,000 |
| Prolia | 759,000,000 | 1,122,000,000 |
| Evenity | 714,000,000 | 518,000,000 |
| Tepezza | 576,000,000 | 505,000,000 |
| Otezla | 491,000,000 | 618,000,000 |
| Enbrel | 580,000,000 | 604,000,000 |
| Blincyto | 472,000,000 | 384,000,000 |
| Nplate | 430,000,000 | 369,000,000 |
| Tezspire | 486,000,000 | 342,000,000 |
| Xgeva | 352,000,000 | 532,000,000 |
| Aranesp | 352,000,000 | 359,000,000 |
| Krystexxa | 400,000,000 | 349,000,000 |
| Kyprolis | 314,000,000 | 378,000,000 |
| Vectibix | 338,000,000 | 305,000,000 |
| Uplizna | 335,000,000 | 176,000,000 |
| Imdelltra imdylltra | 288,000,000 | 134,000,000 |
| Other products | 1,697,000,000 | 1,380,000,000 |
| Total product sales | 9,537,000,000 | 8,771,000,000 |
| Product sales by geography | ||
| United states | 6,990,000,000 | 6,324,000,000 |
| Rest of world | 2,547,000,000 | 2,447,000,000 |
AMGN year-to-date income statement and cash flow
| Six months ended June 30, 2026 | |
|---|---|
| Label | Six months ended June 30, 2026 |
| Period start | 2026-01-01 |
| Period end | 2026-06-30 |
| Period type | six months |
| Source accession | 10-Q |
| Income statement | |
| Product sales | 17,755,000,000.0 |
| Other revenues | 917,000,000.0 |
| Total revenues | 18,672,000,000.0 |
| Cost of sales | 5,555,000,000.0 |
| Research and development | 3,587,000,000.0 |
| Selling general and administrative | 3,347,000,000.0 |
| Other operating expenses | 3,000,000.0 |
| Total operating expenses | 12,492,000,000.0 |
| Operating income | 6,180,000,000.0 |
| Interest expense net | -1,330,000,000.0 |
| Other income expense net | 2,000,000.0 |
| Income before income taxes | 4,852,000,000.0 |
| Provision for income taxes | 658,000,000.0 |
| Net income | 4,194,000,000.0 |
| Basic EPS | 7.77 |
| Diluted EPS | 7.71 |
| Basic shares | 540,000,000.0 |
| Diluted shares | 544,000,000.0 |
| Cash flow | |
| Depreciation amortization and other | 2,228,000,000.0 |
| Impairment of intangible assets | 0.0 |
| Stock based compensation | 240,000,000.0 |
| Operating cash flow | 6,191,000,000.0 |
| Capex | -1,225,000,000.0 |
| Investing cash flow | -1,285,000,000.0 |
| Net proceeds from issuance of debt | 3,964,000,000.0 |
| Extinguishment of debt | -233,000,000.0 |
| Repayment of debt | -833,000,000.0 |
| Dividends paid | -2,720,000,000.0 |
| Financing cash flow | -46,000,000.0 |
| Free cash flow | 4,966,000,000.0 |
| Product sales by product | |
| Repatha | 1,829,000,000.0 |
| Prolia | 1,486,000,000.0 |
| Evenity | 1,276,000,000.0 |
| Tepezza | 1,066,000,000.0 |
| Otezla | 922,000,000.0 |
| Enbrel | 900,000,000.0 |
| Blincyto | 887,000,000.0 |
| Nplate | 842,000,000.0 |
| Tezspire | 829,000,000.0 |
| Xgeva | 763,000,000.0 |
| Aranesp | 663,000,000.0 |
| Krystexxa | 655,000,000.0 |
| Kyprolis | 644,000,000.0 |
| Vectibix | 625,000,000.0 |
| Uplizna | 597,000,000.0 |
| Imdelltra imdylltra | 546,000,000.0 |
| Other products | 3,225,000,000.0 |
| Total product sales | 17,755,000,000.0 |
| Product sales by geography | |
| United states | 12,763,000,000.0 |
| Rest of world | 4,992,000,000.0 |
| Prior year comparative | |
| Label | Six months ended June 30, 2025 |
| Period start | 2025-01-01 |
| Period end | 2025-06-30 |
| Period type | six months |
| Source accession | 10-Q |
| Income statement | |
| Product sales | 16,644,000,000.0 |
| Other revenues | 684,000,000.0 |
| Total revenues | 17,328,000,000.0 |
| Cost of sales | 5,979,000,000.0 |
| Research and development | 3,230,000,000.0 |
| Selling general and administrative | 3,378,000,000.0 |
| Other operating expenses | 907,000,000.0 |
| Total operating expenses | 13,494,000,000.0 |
| Operating income | 3,834,000,000.0 |
| Interest expense net | -1,417,000,000.0 |
| Other income expense net | 1,124,000,000.0 |
| Income before income taxes | 3,541,000,000.0 |
| Provision for income taxes | 379,000,000.0 |
| Net income | 3,162,000,000.0 |
| Basic EPS | 5.88 |
| Diluted EPS | 5.84 |
| Basic shares | 538,000,000.0 |
| Diluted shares | 541,000,000.0 |
| Cash flow | |
| Depreciation amortization and other | 2,728,000,000.0 |
| Impairment of intangible assets | 800,000,000.0 |
| Stock based compensation | 242,000,000.0 |
| Operating cash flow | 3,671,000,000.0 |
| Capex | -780,000,000.0 |
| Investing cash flow | -836,000,000.0 |
| Net proceeds from issuance of debt | 0.0 |
| Extinguishment of debt | -602,000,000.0 |
| Repayment of debt | -3,500,000,000.0 |
| Dividends paid | -2,559,000,000.0 |
| Financing cash flow | -6,780,000,000.0 |
| Free cash flow | 2,891,000,000.0 |
| Product sales by product | |
| Repatha | 1,352,000,000.0 |
| Prolia | 2,221,000,000.0 |
| Evenity | 960,000,000.0 |
| Tepezza | 886,000,000.0 |
| Otezla | 1,055,000,000.0 |
| Enbrel | 1,114,000,000.0 |
| Blincyto | 754,000,000.0 |
| Nplate | 682,000,000.0 |
| Tezspire | 627,000,000.0 |
| Xgeva | 1,098,000,000.0 |
| Aranesp | 699,000,000.0 |
| Krystexxa | 585,000,000.0 |
| Kyprolis | 702,000,000.0 |
| Vectibix | 572,000,000.0 |
| Uplizna | 267,000,000.0 |
| Imdelltra imdylltra | 215,000,000.0 |
| Other products | 2,855,000,000.0 |
| Total product sales | 16,644,000,000.0 |
| Product sales by geography | |
| United states | 11,986,000,000.0 |
| Rest of world | 4,658,000,000.0 |
| Dividends | |
| Dividends declared | 1,280,000,000.0 |
| Dividends declared per share | 2.38 |
| Dividends | |
| Dividends declared | 1,362,000,000.0 |
| Dividends declared per share | 2.52 |
AMGN trailing twelve month income statement and cash flow
| Twelve months ended June 30, 2026 | |
|---|---|
| Label | Twelve months ended June 30, 2026 |
| Period start | 2025-07-01 |
| Period end | 2026-06-30 |
| Period type | trailing twelve months |
| Source accession | 10-Q |
| Derived from accessions | 10-K, 10-Q |
| Income statement | |
| Product sales | 36,259,000,000.0 |
| Other revenues | 1,836,000,000.0 |
| Total revenues | 38,095,000,000.0 |
| Cost of sales | 11,613,000,000.0 |
| Research and development | 7,629,000,000.0 |
| Selling general and administrative | 7,019,000,000.0 |
| Operating income | 11,426,000,000.0 |
| Net income | 8,743,000,000.0 |
| Diluted EPS | 16.1 |
| Cash flow | |
| Operating cash flow | 12,478,000,000.0 |
| Capex | -2,303,000,000.0 |
| Free cash flow | 10,175,000,000.0 |
| Dividends paid | -5,285,000,000.0 |
Adjustments
| Value | |
|---|---|
| Splits applied | none |
| ADR ratio | n/a |
| FX | none; Amgen reports in U.S. dollars |
Notes
- Annual figures for 2025, 2024 and 2023 are taken from the FY2025 Form 10-K (accession 0000318154-26-000010). The 10-K presents three years of income statement and cash flows but only two year-end balance sheets, so FY2023 carries no balance sheet.
- Quarterly figures for the three months ended June 30, 2026 and 2025, the six-month year-to-date figures, and the June 30, 2026 balance sheet are taken from the Q2 2026 Form 10-Q (accession 0000318154-26-000126). The 10-Q does not present a June 30, 2025 balance sheet, so Q2 2025 carries none.
- The 10-Q's cash flow statement covers six months only. The three-month cash flow figures for Q2 2026 and Q2 2025 (operating, investing and financing cash flow, capital expenditures and free cash flow) come from the Q2 2026 earnings release furnished as Exhibit 99.1 to the Form 8-K filed August 4, 2026 (accession 0000318154-26-000124), not from the 10-Q.
- Amgen reports one operating segment, human therapeutics, so the record is organized as a single consolidated business, with product sales broken out by product and by U.S. versus rest of world (ROW) as printed in the revenues note of each filing.
- Free cash flow follows Amgen's own definition: net cash provided by operating activities less capital expenditures. The quarterly and six-month free cash flow figures are printed in the Q2 2026 earnings release; the six-month figures equal the 10-Q's operating cash flow less its purchases of property, plant and equipment. The annual free cash flow is computed from the 10-K's cash flow statement in the same way; the FY2025 ($8,100 million) and FY2024 ($10,394 million) results equal the figures Amgen printed in its fourth-quarter 2025 earnings release (accession 0000318154-26-000003). FY2023 ($7,359 million) equals the figure Amgen printed in its fourth-quarter 2024 earnings release (accession 0000318154-25-000005).
- Capital expenditures are the cash flow statement's 'Purchases of property, plant and equipment' (the earnings release labels the same amount 'Capital expenditures').
- Signs follow the filings: cash outflows and expense amounts printed in parentheses are stored as negative numbers, so interest_expense_net and capex are negative. other_income_expense_net is positive for net other income and negative for net other expense.
- total_debt_derived is the current portion of long-term debt plus long-term debt, at their balance-sheet carrying amounts. The balance sheet prints no total-liabilities line; total_liabilities_derived is the sum of total current liabilities, long-term debt, long-term deferred tax liabilities, long-term tax liabilities and other noncurrent liabilities, and with stockholders' equity it equals total assets in every period.
- No gross profit line is reported because Amgen does not present one. Its cost of sales includes most of the amortization of acquired intangible assets, which the 10-Q puts at $890 million for Q2 2026 and $1.1 billion for Q2 2025.
- Shares outstanding come from the statements of stockholders' equity, which print them in millions to one decimal place. Weighted-average basic and diluted shares are printed in whole millions on the income statement.
- Dividends declared, in total and per share, come from the statements of stockholders' equity. The six-month statements show $2.52 per share declared in 2026 and $2.38 in 2025; the three-month statements for the second quarters of 2026 and 2025 show no dividends declared, so no quarterly dividend-declared figure is given. Dividends paid in cash are in the cash flow block.
- The 10-K names 14 principal products in its revenues note; the 10-Q names 16, adding UPLIZNA and IMDELLTRA/IMDYLLTRA, whose sales the 10-K includes in 'Other products'. 'Other products' therefore covers fewer products in the quarterly and six-month periods than in the annual periods, and the two are not comparable. TEPEZZA and KRYSTEXXA came with the acquisition of Horizon on October 6, 2023, so FY2023 includes only their post-acquisition sales.
- The trailing-twelve-month view is derived, not printed by any filing: FY2025 from the 10-K, plus the six months ended June 30, 2026, less the six months ended June 30, 2025, both from the 10-Q. Its diluted earnings per share ($16.10) is the same arithmetic applied to the published per-share figures ($14.23 + $7.71 - $5.84), not a figure Amgen reports.
- The 10-Q states that certain prior-period amounts were reclassified to conform with the current presentation; the 2025 comparatives here are as presented in the 10-Q.
- No stock split, currency translation or ADR adjustment applies: Amgen reports in U.S. dollars, its common stock trades directly, and it has no stock split in the periods covered.
Uncertainties
- The trailing-twelve-month figures, including the $16.10 diluted earnings per share, are computed from the annual and six-month columns and do not appear in any filing.
- Three-month cash flow figures for Q2 2026 rest on the Q2 2026 earnings release alone, because the 10-Q prints only six-month cash flows. The Q2 2025 three-month figures are also printed in Amgen's Q2 2025 earnings release (accession 0000318154-25-000054).
Company details
| Value | |
|---|---|
| Name | Amgen Inc |
| Ticker | AMGN |
| CIK | 0000318154 |
| Exchange | Nasdaq |
| State | California |
| Incorporation | Delaware |
| SIC | 2836 |
| Office | Life Sciences |
| Industry | Biological Products, (No Diagnostic Substances) |
Fiscal period
| FY2026 | |
|---|---|
| Fiscal year | 2026 |
| Fiscal period | Q2 |
| Tag | FY26Q2 |
| Period end | 2026-06-30 |
| Form | 10-Q |
| Accession | 10-Q |
| Fiscal year end | 1231 |
| Source | facts |
Source filings
| Role | Current | Form | Fiscal year | Fiscal period | Tag | Period end | Filed | Accession | Url | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| annual | no | 10-K | 2025 | FY | FY25 | 2025-12-31 | 2026-02-13 | 0000318154-26-000010 | https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm | reported |
| quarterly | yes | 10-Q | 2026 | Q2 | FY26Q2 | 2026-06-30 | 2026-08-05 | 0000318154-26-000126 | https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/0000318154-26-000126-index.htm | facts |
FAQ · Amgen financial statements
How much revenue did Amgen report in Q2 FY2026?
Amgen reported total revenues of $10.05 billion for Q2 FY2026, the quarter ended June 30, 2026. That is up 9.5% from $9.18 billion in the same quarter a year earlier.
What was Amgen's net income in Q2 FY2026?
Amgen's net income was $2.38 billion in Q2 FY2026, the quarter ended June 30, 2026, up 65.9% from $1.43 billion in the same quarter a year earlier.
What were Amgen's earnings per share in Q2 FY2026?
Amgen earned $4.37 per diluted share in Q2 FY2026, the quarter ended June 30, 2026, up 64.9% from $2.65 in the same quarter a year earlier.
Why did Amgen's profit grow faster than its revenue in Q2 FY2026?
Amgen's operating income rose to $3.51 billion in Q2 FY2026, up 32.3% from $2.66 billion a year earlier, because revenue grew while lower amortization of acquired intangible assets and smaller Horizon inventory step-up charges reduced cost of sales. Net income also benefited from a smaller unrealized loss on Amgen's stake in BeOne Medicines than in the same quarter a year earlier.
Where can I get Amgen Inc. (AMGN) financial data in machine-readable form?
Ticker Scout publishes Amgen Inc.'s financial statements as JSON at https://tickerscout.ai/amgn/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/amgn/narrative.md and https://tickerscout.ai/amgn/events.md. Amgen Inc.'s SEC CIK is 0000318154. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Amgen Inc. (AMGN) next file with the SEC?
Amgen Inc. (AMGN) is expected to file its next Form 10-Q with the SEC on or around November 4, 2026. That date is a projection rather than a company-announced date: it is derived from Amgen Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000318154-26-000126.
Related companies
How this page was built
This page was built from six of Amgen Inc.'s own filings with the SEC, read one at a time. Nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names two such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Amgen Inc.'s SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.